How should I evaluate a 38-year-old woman with abnormal uterine bleeding to rule out a bleeding disorder?

Evaluation of a 38-Year-Old Woman with Abnormal Uterine Bleeding to Rule Out Bleeding Disorder

Screen for bleeding disorders using a focused bleeding history questionnaire, and if positive responses are obtained, order initial coagulation testing including CBC, PT, PTT, and specific von Willebrand disease (VWD) panel (VWF:Ag, VWF:RCo, and Factor VIII levels). 1

Initial Clinical Assessment

Focused Bleeding History Questions

Start with three screening questions for any woman with abnormal uterine bleeding 1:

• Heavy menstrual bleeding since menarche (most predictive for VWD)
• History of postpartum hemorrhage
• Bleeding complications with surgery or dental procedures

If any of these are positive, proceed to the expanded nine-question bleeding assessment tool 1. The presence of menorrhagia since menarche, surgical/dental bleeding, and postpartum hemorrhage are the most discriminatory symptoms for predicting VWD in women with abnormal uterine bleeding 2. Note that epistaxis and easy bruising alone are not clearly discriminatory 2.

Physical Examination Specifics

Look for:

• Ecchymoses, hematomas, petechiae
• Signs of liver disease (jaundice, splenomegaly)
• Joint and skin laxity (Ehlers-Danlos syndrome)
• Telangiectasias (hereditary hemorrhagic telangiectasia)
• Signs of anemia 1

Laboratory Evaluation Algorithm

Initial Hemostasis Tests (Order First)

Complete blood count (CBC), PT, and PTT 1. These don't evaluate for VWD specifically but identify coagulation factor deficiencies or platelet abnormalities.

VWD-Specific Testing (Order Simultaneously if Bleeding History is Strong)

The three essential tests are 1:

• VWF antigen (VWF:Ag)
• VWF ristocetin cofactor activity (VWF:RCo)
• Factor VIII coagulant activity

Critical interpretation point: If the ratio of VWF:RCo to VWF:Ag is below 0.5-0.7, this suggests type 2 VWD and requires specialized testing including multimer analysis 1.

Additional Hemostatic Studies

Based on the clinical picture, consider 2:

• Factor XI level (another common bleeding disorder in women)
• Platelet aggregation studies (20-30% of women with menorrhagia may have impaired platelet aggregation) 2
• Euglobulin clot lysis time (for fibrinolysis disorders)
• Iron profile (to assess chronic blood loss)

Prevalence Context

Von Willebrand disease affects 7-20% of women with menorrhagia 2, making it the most common underlying hemostatic disorder. An additional 20-30% may have platelet aggregation defects 2. This high yield justifies systematic screening in all women with abnormal uterine bleeding.

Common Pitfalls to Avoid

1. Don't assume normal PT/PTT rules out bleeding disorders: VWD and platelet function defects can present with normal routine coagulation tests 1

2. Don't delay VWD testing: If the bleeding history is suggestive, order the VWD panel with the initial visit rather than waiting for basic coagulation results 1

3. Don't forget to rule out pregnancy first: Always obtain a pregnancy test (beta-hCG) in reproductive-aged women before extensive workup 3

4. Don't overlook systemic causes: Check TSH and prolactin levels as part of the initial evaluation, as thyroid dysfunction and hyperprolactinemia are common treatable causes 3

Integration with PALM-COEIN Classification

While evaluating for bleeding disorders (the "C" in COEIN), simultaneously assess for structural causes using the PALM-COEIN framework 3:

• Pregnancy test (mandatory first step)
• TSH and prolactin (for ovulatory dysfunction)
• Transvaginal ultrasound (for structural lesions - polyps, adenomyosis, leiomyomas)
• Endometrial biopsy if age ≥35 years or risk factors for endometrial cancer 4

When to Refer to Hematology

Refer for hemostasis consultation if 1:

• Multiple positive responses on bleeding questionnaire
• Abnormal VWD screening tests
• Abnormal platelet aggregation studies
• Failed medical therapy despite no structural cause
• Adolescents with menorrhagia (higher likelihood of coagulopathy) 5

The failure to diagnose an underlying bleeding disorder leads to continued bleeding, diminished quality of life, and unnecessary surgical interventions that carry increased bleeding risk 2.